复方伊曲康唑滴耳液的临床药效验证试验OA
Clinical Efficacy Verification Trial of Compound Itraconazole Ear Drops
为充分验证复方伊曲康唑滴耳液按推荐剂量使用对犬细菌和真菌引起的外耳道炎的治疗作用和用药方案,试验选用南北两地患有犬细菌和真菌引起的外耳道炎的犬只,每个地点60 只,采用随机对照试验设计,分为复方伊曲康唑滴耳液受试药物组和复方克霉唑软膏对照药物组,每个地点每组30 只,各试验组均连续给药 14 d,每日 2 次.在试验开始前(SD0 给药前)、给药过程中(SD2±1/SD4±1/SD 7±1)、停药后(SD14/SDn)对试验犬进行评估,观察并记录受试犬的体温、呼吸、心跳、精神状态、食欲、饮欲等一般临床症状和外耳道皮肤充血、水肿、瘙痒、有耳道分泌物等犬的细菌、真菌性外耳道炎的特定临床症状;在试验开始前(SD0 给药前)、给药过程中(SD7±1)、停药后(SD14/SDn)采集试验犬的外周血样并对病灶进行取样,对采集样品进行血常规、血液生化检测和微生物学检查,进行指示菌计数记录结果.以各组试验犬的特定症状下降指数和致病菌分离转阴率为主要观察指标,进一步验证复方伊曲康唑滴耳液推荐剂量治疗犬细菌和真菌引起的外耳道炎的治疗效果.试验结果表明,在试验过程中复方伊曲康唑滴耳液组的主要疗效指标出现持续性好转.根据特定症状评分、特定症状下降指数和致病菌转阴率结果综合评判受试犬治疗效果,在给药第7d 时,受试药复方伊曲康唑滴耳液的治愈率和对照药复方克霉唑软膏的治愈率达到显效标准(全组治愈率⫺80%),治愈率分别为95.00%和91.67%,在给药14 d 时受试药复方伊曲康唑滴耳液的治愈率和对照药复方克霉唑软膏的治愈率分别为98.33%和95.00%,且两组之间治愈率无显著差异,说明复方伊曲康唑滴耳液在推荐剂量下连用 14 日为最佳给药方案,对犬细菌和真菌引起的外耳道炎的治疗有效且安全.
This study was conducted to fully verify the therapeutic effect and optimal dosage regimen of compound itraconazole ear drops at the recommended dose for canine otitis externa caused by bacteria and fungi,a randomized controlled trial was conducted on dogs diagnosed with bacterial and fungal otitis externa at two sites(northern and southern regions),with 60 dogs enrolled at each location.The dogs were randomly divided into a test group treated with compound itraconazole ear drops and a control group treated with compound clotrimazole ointment,with 30 dogs per group at each site.All dogs were administered the corresponding medication twice daily for 14 consecutive days.Evaluations were performed before treatment(SD0),during treatment(SD2±1,SD4±1,SD7±1),and after treatment(SD14/SDn).General clinical conditions including body temperature,respiration,heart rate,mental status,appetite,and water intake were recorded,as well as specific clinical signs of otitis externa such as aural congestion,edema,pruritus,and ear discharge.Peripheral blood and lesion samples were collected before treatment(SD0),during treatment(SD7±1),and after treatment(SD14/SDn)for routine blood analysis,blood biochemistry,and microbiological examination,including quantitative culture and counting of indicator pathogens.The primary outcome measures included the specific symptom reduction index and the negative conversion rate of pathogenic bacteria and fungi,to further confirm the therapeutic efficacy of compound itraconazole ear drops at the recommended dose.The results showed that the main efficacy indicators in the compound itraconazole ear drops group improved continuously throughout the trial.Based on comprehensive evaluation using specific symptom scores,symptom reduction indices,and pathogen negative conversion rates,the curative effects of both the test drug and the control drug reached the marked effective standard(group cure rate≥80%)on day 7 of treatment,with cure rates of 95.00%and 91.67%,respectively.On day 14 of treatment,the cure rates were 98.33%for compound itraconazole ear drops and 95.00%for compound clotrimazole ointment,with no significant difference between the two groups.These results indicate that 14 consecutive days of administration at the recommended dose is the optimal regimen for compound itraconazole ear drops,which is effective and safe for the treatment of canine bacterial and fungal otitis externa.
贺倩倩;尹伶灵;章安源;张会梅;付海宁;姚德勇;陈昱骁;林扬;陈玲;孙亚磊
青岛蔚蓝至宠生物科技有限公司,山东 青岛 266041山东省饲料兽药质量检验中心,济南 250102山东省饲料兽药质量检验中心,济南 250102青岛蔚蓝至宠生物科技有限公司,山东 青岛 266041青岛蔚蓝至宠生物科技有限公司,山东 青岛 266041青岛蔚蓝至宠生物科技有限公司,山东 青岛 266041青岛蔚蓝至宠生物科技有限公司,山东 青岛 266041青岛蔚蓝至宠生物科技有限公司,山东 青岛 266041山东省饲料兽药质量检验中心,济南 250102青岛蔚蓝生物股份有限公司,山东 青岛 266000
农业科技
复方伊曲康唑滴耳液犬外耳道炎临床药效细菌和真菌
compound itraconazole ear dropsdogsotitis externaclinical efficacybacterial and fungal
《中国兽药杂志》 2026 (5)
14-23,10
山东省重点研发计划(2023CXPT058)山东省泰山产业领军人才(TSCX202408137)
评论